Linked Life Data

15373779

Source:http://linkedlifedata.com/resource/pubmed/id/15373779

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2004-9-17
pubmed:abstractText
Cytokine resistance is a well-established feature of melanoma cell progression and represents also a major obstacle in immunotherapy of patients with metastatic melanoma. To check whether suppressors of cytokine signalling (SOCS) play a role in cytokine resistance and tumor progression of melanoma, we investigated the expression and regulation of SOCS-1, an established negative regulator of interleukin-6 (IL-6) and interferon (IFN) signalling. In vitro SOCS-1 transcripts were detectable by RT-PCR in 8 out of 8 human melanoma cell lines derived from different tumor stages. Normal human melanocytes also expressed SOCS-1 mRNA in the presence or absence of artificial growth factors. Both IL-6 and alpha-IFN induced rapid and transient SOCS-1 mRNA expression in WM35 and WM9 melanoma cells. At the protein level, SOCS-1 was undetectable in normal human melanocytes whereas uniformly expressed in all tested melanoma cell lines. The aberrant SOCS-1 protein expression in melanoma cells was recapitalized in situ as shown by immunohistochemical analysis. SOCS-1 immunoreactivity was closely related to tumor invasion (Clark level), tumor thickness according to Breslow, and stage of the disease. In contrast, melanocytes in normal skin or melanocytic nevi lacked SOCS-1 protein expression. Our findings show that melanoma cells express a member of the SOCS family, SOCS-1, in vitro and in situ. SOCS-1 is a progression marker of human melanoma and may downregulate biological responses by endogenous and/or therapeutically administered cytokines.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0022-202X
pubmed:author
pubmed:issnType
Print
pubmed:volume
123
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
737-45
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15373779-Antineoplastic Agents, pubmed-meshheading:15373779-Carcinoma in Situ, pubmed-meshheading:15373779-Carrier Proteins, pubmed-meshheading:15373779-Cell Line, Tumor, pubmed-meshheading:15373779-Cell Transformation, Neoplastic, pubmed-meshheading:15373779-Gene Expression Regulation, Neoplastic, pubmed-meshheading:15373779-Humans, pubmed-meshheading:15373779-Interferon-alpha, pubmed-meshheading:15373779-Interleukin-6, pubmed-meshheading:15373779-Intracellular Signaling Peptides and Proteins, pubmed-meshheading:15373779-Melanoma, pubmed-meshheading:15373779-RNA, Messenger, pubmed-meshheading:15373779-Repressor Proteins, pubmed-meshheading:15373779-Skin Neoplasms, pubmed-meshheading:15373779-Suppressor of Cytokine Signaling Proteins, pubmed-meshheading:15373779-Tumor Markers, Biological
pubmed:year
2004
pubmed:articleTitle
Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma.
pubmed:affiliation
Department of Dermatology and Ludwig Boltzmann Institute for Cell Biology and Immunobiology of the Skin, University of Münster, Münster, Germany.
pubmed:publicationType
Journal Article, In Vitro, Research Support, Non-U.S. Gov't